BACKGROUND: Prader Willi syndrome (PWS) without strict environmental modifications can lead to obesity associated with significant morbidity and mortality. In addition to increased appetite, these individuals have decreased energy expenditure with lower insulin like growth factor 1 (IGF1), which contributes to adiposity. No effective treatment is available for this condition. Endocannabinoid receptor CB1 antagonist, rimonobant, has been effective for treatment of obesity in adult subjects. Rimonabant promotes weight loss by multiple proposed mechanisms, including decreased appetite and lipogenesis, and increased energy expenditure. Therefore, we conducted this pilot study to evaluate the effect of rimonabant on body weight and composition of adults with PWS. METHOD: This was a double blind placebo controlled study. Body weight, total fat mass, fasting ghrelin, leptin, IGF1 and insulin like growth factor binding protein (IGFBP-3) were collected at baseline, and after 90 and 180 days of treatment with placebo or 20 mg of rimonabant. RESULTS: Due to psychiatric adverse effects, 50% of subjects in the rimonabant group withdrew, and the study was terminated early (N=10) for safety concerns. There was a trend for weight loss, lower fat mass and higher IGF1 level at the end of study in this group. Leptin followed the fat mass and decreased with rimonabant treatment. CONCLUSION:Rimonabant administration may be efficacious for weight loss in adults with PWS; unfortunately it is associated with an unacceptably high risk of psychiatric side effects. Future CB1 antagonists will need a better psychiatric profile before considered in the treatment of obesity in this genetic condition.
RCT Entities:
BACKGROUND:Prader Willi syndrome (PWS) without strict environmental modifications can lead to obesity associated with significant morbidity and mortality. In addition to increased appetite, these individuals have decreased energy expenditure with lower insulin like growth factor 1 (IGF1), which contributes to adiposity. No effective treatment is available for this condition. Endocannabinoid receptor CB1 antagonist, rimonobant, has been effective for treatment of obesity in adult subjects. Rimonabant promotes weight loss by multiple proposed mechanisms, including decreased appetite and lipogenesis, and increased energy expenditure. Therefore, we conducted this pilot study to evaluate the effect of rimonabant on body weight and composition of adults with PWS. METHOD: This was a double blind placebo controlled study. Body weight, total fat mass, fasting ghrelin, leptin, IGF1 and insulin like growth factor binding protein (IGFBP-3) were collected at baseline, and after 90 and 180 days of treatment with placebo or 20 mg of rimonabant. RESULTS: Due to psychiatric adverse effects, 50% of subjects in the rimonabant group withdrew, and the study was terminated early (N=10) for safety concerns. There was a trend for weight loss, lower fat mass and higher IGF1 level at the end of study in this group. Leptin followed the fat mass and decreased with rimonabant treatment. CONCLUSION:Rimonabant administration may be efficacious for weight loss in adults with PWS; unfortunately it is associated with an unacceptably high risk of psychiatric side effects. Future CB1 antagonists will need a better psychiatric profile before considered in the treatment of obesity in this genetic condition.
Authors: Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: Douglas Osei-Hyiaman; Jie Liu; Liang Zhou; Grzegorz Godlewski; Judith Harvey-White; Won-il Jeong; Sándor Bátkai; Giovanni Marsicano; Beat Lutz; Christoph Buettner; George Kunos Journal: J Clin Invest Date: 2008-09 Impact factor: 14.808
Authors: Andrea M Haqq; Steven C Grambow; Michael Muehlbauer; Christopher B Newgard; Laura P Svetkey; Aaron L Carrel; Jack A Yanovski; Jonathan Q Purnell; Michael Freemark Journal: Clin Endocrinol (Oxf) Date: 2008-08-15 Impact factor: 3.478
Authors: Jennifer L Miller; Anthony P Goldstone; Jessica A Couch; Jonathan Shuster; Guojun He; Daniel J Driscoll; Yijun Liu; Ilona M Schmalfuss Journal: Am J Med Genet A Date: 2008-03-01 Impact factor: 2.802
Authors: Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler Journal: Diabetes Obes Metab Date: 2017-07-13 Impact factor: 6.577
Authors: Ibrahim Knani; Brian J Earley; Shiran Udi; Alina Nemirovski; Rivka Hadar; Asaad Gammal; Resat Cinar; Harry J Hirsch; Yehuda Pollak; Itai Gross; Talia Eldar-Geva; Daniela P Reyes-Capo; Joan C Han; Andrea M Haqq; Varda Gross-Tsur; Rachel Wevrick; Joseph Tam Journal: Mol Metab Date: 2016-10-22 Impact factor: 7.422
Authors: Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller Journal: Mol Genet Genomic Med Date: 2019-01-29 Impact factor: 2.183
Authors: Mayara C F Gewehr; Renata Silverio; José Cesar Rosa-Neto; Fabio S Lira; Patrícia Reckziegel; Emer S Ferro Journal: Molecules Date: 2020-02-29 Impact factor: 4.411